TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
---|---|---|---|---|---|---|---|---|---|---|---|
S | %ret | 1 | 1 | 1 | 0 | 4 | 40 | 28 | 35 | 89 | 39 |
S | %wins | 100 | 0 | 0 | 0 | 0 | 0 | 17 |
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
5/12/22 16:22 | 5/10/22 | MRNA | Moderna, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Nader Francois | MA | D | S.d | -435 | 136.10 | 0 | -3 | -13 | 21 | D | |||||||||||||||
9/30/13 18:23 | 9/26/13 | NPSP | Nps Pharmaceuticals Inc | DE | Health | BioPrd | Biological Products, (No Diag | Nader Francois | NJ | DO | P,CEO,Di | S.dm | -6,370 | 32.93 | 0 | -193 | -69 | 88 | D | ||||||||||||||
4/10/13 18:19 | 4/8/13 | NPSP | Nps Pharmaceuticals Inc | DE | Health | BioPrd | Biological Products, (No Diag | Nader Francois | NJ | DO | P,CEO,Di | S.dm | -5,073 | 11.31 | 0 | -448 | -67 | 217 | D | ||||||||||||||
4/2/10 14:30 | 2/3/10 | NPSP | Nps Pharmaceuticals Inc | DE | Health | BioPrd | Biological Products, (No Diag | Nader Francois | NJ | DO | P,CEO,Di | S | -65 | 3.37 | 1 | -19 | -11 | 150 | D | 23 | 23 | 26 | 42 | 52 | 28 | 21 | 4 | 0 | 4 | 40 | 28 | 35 | 89 |
D | Derivative transaction in filing (usually option exercise) |
M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
A | Amended filing |
E | Error detected in filing |
S - Sale | Sale of securities on an exchange or to another person |
S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
P - Purchase | Purchase of securities on an exchange or from another person |